In order to verify the accuracy and specificity of these three lncRNAs (MEG3, SNHG16 and MALAT1) as the BC signature, we assessed their expression levels using another independent sample set containing 48 healthy subjects, 52 benign disease and 100 BC patients (Supplementary Figure S1 and Supplementary Figure S2). This evidence concerns the gene MEG3 and breast cancer.